Treatment of adenoviral keratoconjunctivitis with a combination of povidone‐iodine 1.0% and dexamethasone 0.1% drops: a clinical prospective controlled randomized study

Purpose To determine the efficacy of combination povidone‐iodine (PVP‐I) 1.0% eyedrops and dexamethasone 0.1% eyedrops in the treatment of adenoviral keratoconjunctivitis. Materials and methods In a prospective, randomized, controlled, double‐blinded clinical trial patients with recent adenoviral keratoconjunctivitis (diagnosed clinically and confirmed by PCR ), we randomly divided into three treatment groups: study group – received PVP‐I 1.0% and dexamethasone 0.1%, control 1 group – received dexamethasone 0.1% and control 2 group – received lubricating eyedrops (hypromellose 0.3%). The treatment was administered four times a day in each group. All patients were examined and filled a questionnaire before treatment and on the 3rd, 5th and 7th days of treatment. Results We included in the study 78 eyes (26 in each group). Adenovirus type 8 was the most common pathogen (83% of cases). The fastest improvement in patients red eyes, discharge, superficial punctate keratitis and pseudomembranes was observed in the study group (p < 0.001). Those patients reached a near complete recovery in 5–7 days, which was also confirmed by reduction in Adenovirus titres by PCR . The slowest improvement was in the control 2 group. Subepithelial infiltrates (SEI) were observed in 44% of the control 1 group, 20% of the control 2 group and in 0% of the study group. The rate of reduction in Adenovirus titres was the slowest in the control 1 group. Conclusion The combination of PVP‐I 1.0% and dexamethasone 0.1% four times a day can reduce symptoms and expedite recovery in epidemic keratoconjunctivitis patients.